Invitrogen Evaluates Portfolio as Acquisition Integrations, Limp Sera Sales Weigh on Q2 Revs | GenomeWeb
Following a quarter in which sales of its sera products declined sharply, Invitrogen officials said last week that they are reviewing the firm’s entire portfolio with a particular focus on the sera business.
 
Additionally, though the officials declined to say whether a divestment of that business was possible, Chairman and CEO Greg Lucier said the firm is currently reviewing whether “we need to be broadly in the sera business” and hopes to know more in six months.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.